Keyword: Department of Health and Human Services (HHS)
Sticker prices in drug ads might be off the table again, thanks to some in the U.S. House of Representatives.
After HHS proposed a rule that would shake up or eliminate drug rebates, a watchdog wants to know if agency chief Alex Azar has ulterior motives.
The Senate voted in favor of drug pricing in DTC ads, while HHS works on a transparency proposal for Medicare and Medicaid.
Louisiana has proposed a "subscription-based payment model" for hepatitis C drugs it hopes can benefit the state and drugmakers alike.
Think President Trump's bid to slap price tags on drug ads is all talk? Think again. In recent days, the idea has gained steam—and bipartisan backing.
Sen. Ron Wyden wants to know more about why Pfizer CEO Ian Read agreed to defer the company's July price hikes.
President Trump convinced one pharma giant to retreat on price increases, and it’s not good news for other price-hiking drugmakers.
CMS has pulled the plug on a plan to implement indication-specific pricing on Novartis' CAR-T drug Kymriah.
Alex Azar said drug companies are "actually competing with each other" to lower prices but want to make sure PBMs won't discriminate against them.
President Trump's new pick for CDC director voiced unequivocal support for immunizations.